SNMMI: Carson discusses Image of the Year

Will Morton
Jun 11, 2024

AuntMinnie.com spoke with Richard Carson, PhD, from Yale University, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting about the society's 2024 Image of the Year.

The award was given for a study using a new ultrahigh resolution dedicated brain PET system Carson and colleagues developed called the NeuroExplorer.

Click here for our full SNMMI coverage.

Latest in 2024
Prostate Imaging2
Treatment paradigm shifting for men with prostate cancer
June 28, 2024
Brain Puzzle Dementia
SNMMI: PET/CT illuminates connection between CVD and cognitive impairment
June 12, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
SNMMI: PET-based protocol shows promise in radioligand therapy
June 12, 2024
Oliver Sartor, MD
SNMMI: Lu-177 PSMA-617 shines for taxane-naive prostate cancer
June 11, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
Nadel 666768f41cb5b Thumbnail
2024
SNMMI: Nuclear medicine experiencing an ‘industrial revolution’
Ora Israel Thumbnail
2024
SNMMI: Nuclear medicine clinician-scientists need passion, stamina
The company's MINItrace Magni in-house cyclotron.
2024
GE HealthCare highlights new cyclotron at SNMMI 2024
More in 2024
Treatment paradigm shifting for men with prostate cancer
By Will Morton
New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC).
June 28, 2024
Prostate Imaging2
SNMMI: PET/CT illuminates connection between CVD and cognitive impairment
By Kate Madden Yee
PET/CT reveals a connection between cardiovascular disease (CVD) and cognitive impairment, according to research presented at SNMMI 2024.
June 12, 2024
Brain Puzzle Dementia
SNMMI: PET-based protocol shows promise in radioligand therapy
By Amerigo Allegretto
A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.
June 12, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
SNMMI: Lu-177 PSMA-617 shines for taxane-naive prostate cancer
By Erik L. Ridley
The radiopharmaceutical Pluvicto improves survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy.
June 11, 2024
Oliver Sartor, MD
SNMMI: UW advances radioimmunotherapy At-211 production, trials
By Liz Carey
Alpha-emitting astatine-211 (At-211) may open the door to new targeted radioimmunotherapy for treating blood cancer.
June 11, 2024
Preclinical multiple myeloma studies at the University of Washington, presented during SNMMI 2024, show survival of mice at different intervals and doses of the alpha radioimmunotherapy At-211-CD38. Graphic and caption courtesy of Yawen Li, PhD.
SNMMI: FAPI PET/CT shows promise in breast cancer staging
By Amerigo Allegretto
A study presented at SNMMI suggests that FAPI PET/CT could be suitable for systemic staging of newly diagnosed breast cancer.
June 11, 2024
Clinical stage changed by FAPI PET/CT categorized by F-18 FDG PET/CT in newly diagnosed breast cancer.
SNMMI: Study explores theranostic ‘cocktail’ for colon cancer
By Will Morton
An animal study shows the feasibility of an approach in colon cancer that simultaneously uses alpha- and beta-emitting isotopes to target and kill cancer cells.
June 11, 2024
An autoradiography image showing the simultaneous biodistribution of Lutetium-177 and Actinium-225 radionuclides in colon cancer xenografts in mice.
SNMMI: Ultralow dose PET protocol eliminates need for CT
By Kate Madden Yee
A new ultralow dose imaging method used with long axial field-of-view PET scanners produces images with a radiopharmaceutical dose 50 times lower than the standard effective dose.
June 11, 2024
Top row: CT- and LSO-TX-based attenuation maps with their respective percentage relative change (%RC) map. Bottom row: PET images reconstructed using CT- and LSO-TX-based attenuation maps with their respective %RC map. Image and caption courtesy of the SNMMI.
SNMMI: Nuclear medicine experiencing an ‘industrial revolution’
By Erik L. Ridley
Recent growth in nuclear medicine has represented the equivalent of an “industrial revolution" for specialty, according to SNMMI President Helen Nadel, MD.
June 10, 2024
Nadel 666768f41cb5b Thumbnail
SNMMI: Nuclear medicine clinician-scientists need passion, stamina
By Erik L. Ridley
Ora Israel, MD, shares what it takes to succeed as a nuclear medicine clinician-scientist in a video interview at SNMMI 2024.
June 10, 2024
Ora Israel Thumbnail
GE HealthCare highlights new cyclotron at SNMMI 2024
By AuntMinnie.com staff writers
GE HealthCare introduced the MINItrace Magni at the Society of Nuclear Medicine and Molecular Imaging annual meeting (SNMMI) annual meeting, a newly designed, small-footprint cyclotron for in-house production of commercial PET radiotracers.
June 10, 2024
The company's MINItrace Magni in-house cyclotron.
SNMMI taps Urbain as president-elect
By AuntMinnie.com staff writers
Jean-Luc Urbain, MD, PhD, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
June 10, 2024
Jean Luc Urbain Md Ph D V Pelect Snmmi 2024
Page 1 of 3
Next Page